Express News | Ventyx Biosciences Inc: Expect to Report Topline Results From This Trial in 2025.
Express News | Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of Vtx3232 in Patients With Early Parkinson’s Disease
Express News | Ventyx Biosciences: Roy Gonzales Assumed Roles of Interim Principal Financial Officer and Interim Principal Accounting Officer
Express News | Ventyx Biosciences Announces Departure of Chief Financial Officer
Press Release: Ventyx Biosciences Announces Departure of Chief Financial Officer
Ventyx Biosciences to Participate in Two Upcoming Investor Conferences